A pilot study on the impact of congenital thrombophilia in COVID-19

Eur J Clin Invest. 2021 May;51(5):e13546. doi: 10.1111/eci.13546. Epub 2021 Mar 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antithrombin III / genetics
  • Antithrombin III Deficiency / blood
  • Antithrombin III Deficiency / complications
  • Antithrombin III Deficiency / genetics
  • COVID-19 / blood*
  • COVID-19 / complications
  • COVID-19 / physiopathology
  • Cohort Studies
  • Factor V Deficiency / blood
  • Factor V Deficiency / complications
  • Factor V Deficiency / genetics
  • Female
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Hypoprothrombinemias / blood
  • Hypoprothrombinemias / complications
  • Hypoprothrombinemias / genetics
  • Intensive Care Units / statistics & numerical data
  • Logistic Models
  • Male
  • Middle Aged
  • Mortality
  • Pilot Projects
  • Protein C / genetics
  • Protein C Deficiency / blood
  • Protein C Deficiency / complications
  • Protein C Deficiency / genetics
  • Protein S / genetics
  • Protein S Deficiency / blood
  • Protein S Deficiency / complications
  • Protein S Deficiency / genetics
  • Respiratory Distress Syndrome / blood
  • Respiratory Distress Syndrome / physiopathology
  • SARS-CoV-2
  • Severity of Illness Index
  • Thrombophilia / blood*
  • Thrombophilia / complications
  • Thrombophilia / genetics
  • Thrombophilia / physiopathology
  • Thrombosis / blood*
  • Thrombosis / physiopathology

Substances

  • Fibrin Fibrinogen Degradation Products
  • PROS1 protein, human
  • Protein C
  • Protein S
  • SERPINC1 protein, human
  • fibrin fragment D
  • Antithrombin III